AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19710187 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months (EBF6)
Number of subjects: 2951
Study 19710187 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding for 3 months (EBF3)
Number of subjects: 2951
Study 18986747 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperSeal
Number of subjects: 125
Study 18986747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 125
Study 18986747 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-Coat
Number of subjects: 125
Study 18986747 — intervention group
Group type: EXPERIMENTAL
Intervention: Copalite Varnish
Number of subjects: 125
Study 18986747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 15824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching (2-6 hours per day) combined with near visual activities and atropine sulfate for children aged 7 to 12 years
Number of subjects: 507
Study 15824215 — intervention group
Group type: COMPARATOR
Intervention: Optical correction alone
Number of subjects: 507
Study 15824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching (2-6 hours per day) combined with near visual activities
Number of subjects: 507
Study 12584535 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine (2-dose regimen)
Number of subjects: 29
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine-resistant isolates (IC50 >= 100 nM) with 16 repeat units in the omega region
Number of subjects: 75
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine-sensitive isolates (IC50 < 100 nM) with 16 repeat units in the omega region
Number of subjects: 75
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with treatment failure infected with parasites carrying 16 repeat units
Number of subjects: 75
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients showing adequate clinical response with isolates carrying 16 repeat units
Number of subjects: 75
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients showing adequate clinical response with isolates carrying < or = 15 or > or = 17 repeat units
Number of subjects: 75
Study 10586916 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity, specificity, and predictive value of the test
Number of subjects: 75
Study 10586916 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and in vivo resistance to chloroquine
Number of subjects: 75
Study 8901824 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism
Number of subjects: 70
Study 8901824 — intervention group
Group type: EXPERIMENTAL
Intervention: Renovascular hypertension
Number of subjects: 70
Study 8901824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 70
Study 8901824 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertension
Number of subjects: 70
Study 8901824 — intervention group
Group type: EXPERIMENTAL
Intervention: All hypertensive groups
Number of subjects: 70
Study 8901824 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive subjects and essential hypertension)
Number of subjects: 70
Study 1806475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg, p.o.)
Number of subjects: 14
Study 1806475 — intervention group
Group type: COMPARATOR
Intervention: GHRH plus placebo (2 tablets, p.o.)
Number of subjects: 14
Study 6626904 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antibiotic prophylaxis after urodynamic investigation
Number of subjects: 96
Study 6626904 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (implied control)
Number of subjects: 96
Study 30215342 — intervention group
Group type: COMPARATOR
Intervention: Poor dietary pattern
Number of subjects: 521
Study 28604824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC/FTC
Number of subjects: 33
Study 28604824 — intervention group
Group type: COMPARATOR
Intervention: cART
Number of subjects: 33
Study 27206951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 2 weeks (Q2W)
Number of subjects: 63
Study 27206951 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks (Q2W)
Number of subjects: 63
Study 24052500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 119
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at 3 to 4 days after hemorrhage
Number of subjects: 2106
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at 5 to 10 days after hemorrhage
Number of subjects: 2106
Study 22700527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment >10 days after hemorrhage
Number of subjects: 2106
Study 19710213 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional strategy (clinical monitoring and DUS surveillance every 3 months, followed by PTA for stenosis of 50% or greater)
Number of subjects: 108
Study 19710213 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional strategy
Number of subjects: 108
Study 19710213 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care: clinical and hemodynamic NAF assessment followed by vascular surgeon consultation)
Number of subjects: 108
Study 17268695 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO and ACE inhibitors/ARBs
Number of subjects: 100
Study 17268695 — intervention group
Group type: COMPARATOR
Intervention: rHuEPO with other antihypertensives (calcium channel blockers or beta-adrenergic receptor blockers)
Number of subjects: 100
Study 15470329 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg single dose)
Number of subjects: 29
Study 11398172 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal examination as initial screening test
Number of subjects: 20979
Study 11398172 — intervention group
Group type: COMPARATOR
Intervention: PSA screening only (cut-off of 3.0 ng/ml)
Number of subjects: 20979
Study 11398172 — intervention group
Group type: COMPARATOR
Intervention: Rectal examination
Number of subjects: 20979
Study 10339045 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Ambassador intervention (N = 89)
Number of subjects: 171
Study 10339045 — intervention group
Group type: COMPARATOR
Intervention: Standard care (N = 82)
Number of subjects: 171
Study 7992843 — intervention group
Group type: EXPERIMENTAL
Intervention: rPDGF-BB
Number of subjects: 20
Study 7992843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2567372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol (4 mg/kg every 2 weeks for the first month then monthly) and zidovudine
Number of subjects: 51
Study 2567372 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 51
Study 2567372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol
Number of subjects: 51
Study 2567372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol and zidovudine
Number of subjects: 51
Study 31054551 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure irrigation and suction
Number of subjects: 80
Study 31054551 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 80
Study 28110468 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased breakfast eating during treatment
Number of subjects: 0
Study 28110468 — intervention group
Group type: EXPERIMENTAL
Intervention: No change or decrease in daily eating frequency
Number of subjects: 0
Study 28110468 — intervention group
Group type: COMPARATOR
Intervention: Baseline breakfast eating and eating frequency
Number of subjects: 0
Study 28110468 — intervention group
Group type: COMPARATOR
Intervention: Changes in eating frequency
Number of subjects: 0
Study 25540862 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 158
Study 25540862 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered behavioral stress management (IBSM)
Number of subjects: 158
Study 25540862 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT and IBSM
Number of subjects: 158
Study 23255691 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of measles vaccine (study group)
Number of subjects: 78
Study 23255691 — intervention group
Group type: COMPARATOR
Intervention: Single dose of measles vaccine (control group)
Number of subjects: 78
Study 21932660 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLADS
Number of subjects: 30
Study 21932660 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 30
Study 19050085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentastarch (500 mL - maximum 3 L or 28 mL x kg(‐1))
Number of subjects: 40
Study 19050085 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (blinded)
Number of subjects: 40
Study 16584102 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Family Therapy (BFT)
Number of subjects: 24
Study 16584102 — intervention group
Group type: COMPARATOR
Intervention: Individual usual treatment
Number of subjects: 24
Study 12869126 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 sec)
Number of subjects: 0
Study 12869126 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 0
Study 10937953 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 21
Study 10937953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8522716 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position
Number of subjects: 16
Study 8522716 — intervention group
Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position
Number of subjects: 16
Study 8522716 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position (normal heart size)
Number of subjects: 16
Study 8522716 — intervention group
Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position (normal heart size)
Number of subjects: 16
Study 8522716 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position (enlarged heart)
Number of subjects: 16
Study 8522716 — intervention group
Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position (enlarged heart)
Number of subjects: 16
Study 1841044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg twice daily for 10 days
Number of subjects: 12
Study 6867623 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urethral catheterisation
Number of subjects: 76
Study 6867623 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic cystostomy
Number of subjects: 76
Study 30779689 — intervention group
Group type: EXPERIMENTAL
Intervention: Shz‐IIV3
Number of subjects: 1599
Study 30779689 — intervention group
Group type: COMPARATOR
Intervention: Comparator IIV3
Number of subjects: 1599
Study 30280390 — intervention group
Group type: EXPERIMENTAL
Intervention: IV SNF472 9 mg kg–1 in HD patients
Number of subjects: 28
Study 30280390 — intervention group
Group type: COMPARATOR
Intervention: Placebo in HD patients
Number of subjects: 28
Study 28978344 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise programme
Number of subjects: 0
Study 28978344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study 26624824 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (≤2000 mg/d)
Number of subjects: 140
Study 26624824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 23988146 — intervention group
Group type: EXPERIMENTAL
Intervention: MS‐MO/UPE
Number of subjects: 26
Study 23988146 — intervention group
Group type: COMPARATOR
Intervention: MS‐SO/UPE
Number of subjects: 26
Study 26086980 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Nurse Family Partnership Study (ENFPS)
Number of subjects: 0
Study 18941075 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-associated autologous chondrocyte transplantation
Number of subjects: 15
Study 16581161 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 peptide vaccine
Number of subjects: 128
Study 16581161 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly‐L‐arginine
Number of subjects: 128
Study 16581161 — intervention group
Group type: COMPARATOR
Intervention: HCV peptides alone
Number of subjects: 128
Study 16581161 — intervention group
Group type: COMPARATOR
Intervention: Poly‐l‐arginine alone
Number of subjects: 128
Study 16581161 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 128
Study 12700622 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA 50:50 (50% c9,t11 CLA and 50% t10,c12 CLA isomers)
Number of subjects: 71
Study 12700622 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA 80:20 (80% c9,t11 CLA and 20% t10,c12 CLA isomers)
Number of subjects: 71
Study 12700622 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil fatty acids (reference)
Number of subjects: 71
Study 11144440 — intervention group
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid-enriched formula (0.35% of total fatty acids)
Number of subjects: 87
Study 11144440 — intervention group
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid- (0.36%) and arachidonic acid- (0.72%) enriched formula
Number of subjects: 87
Study 11144440 — intervention group
Group type: COMPARATOR
Intervention: commercial formula
Number of subjects: 87
Study 11144440 — intervention group
Group type: COMPARATOR
Intervention: human milk
Number of subjects: 87
Study 9335414 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 82
Study 9335414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 82
Study 9335414 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 82
Study 9335414 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 82
Study 9335414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 82
Study 9335414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 7678314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 90
Study 7678314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3741530 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen sustained release 600 mg tablets
Number of subjects: 60
Study 3741530 — intervention group
Group type: COMPARATOR
Intervention: indometacin sustained release 75 mg capsules
Number of subjects: 60
Study 28732220 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of impacted mandibular third molars
Number of subjects: 60
Study 27310329 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device with activated charcoal
Number of subjects: 0
Study 27310329 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device without activated charcoal
Number of subjects: 0
Study 27310329 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 300 μg inhaled via Breezhaler (BRZ) device
Number of subjects: 0
Study 27310329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinsing after inhalation
Number of subjects: 0
Study 27310329 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 24615306 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute treatments 2 times weekly
Number of subjects: 228
Study 24615306 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute treatments 3 times weekly
Number of subjects: 228
Study 24615306 — intervention group
Group type: COMPARATOR
Intervention: 30-minute treatments
Number of subjects: 228
Study 23545865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal dexmedetomidine (DEX) 0.5 μg/kg and bupivacaine 0.25%, 2.5 mg/kg
Number of subjects: 40
Study 23545865 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/kg and fentanyl 1 μg/kg
Number of subjects: 40
Study 20152050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac treatment
Number of subjects: 0
Study 20152050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18230015 — intervention group
Group type: EXPERIMENTAL
Intervention: RIDcancerPain
Number of subjects: 176
Study 18230015 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 176
Study 16633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg LD/7.5 mg MD
Number of subjects: 31
Study 16633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD/15 mg MD
Number of subjects: 31
Study 16633079 — intervention group
Group type: COMPARATOR
Intervention: Placebo LD/Placebo MD
Number of subjects: 31
Study 16633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 7.5 mg MD
Number of subjects: 31
Study 16633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 15 mg MD
Number of subjects: 31
Study 16633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (both doses)
Number of subjects: 31
Study 12744408 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer (Ketac Bond)
Number of subjects: 100
Study 12744408 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Vitremer)
Number of subjects: 100
Study 12744408 — intervention group
Group type: COMPARATOR
Intervention: Control group (108 children, 432 teeth)
Number of subjects: 100
Study 10996520 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8825251 — intervention group
Group type: EXPERIMENTAL
Intervention: Staffed group living situation
Number of subjects: 112
Study 8825251 — intervention group
Group type: COMPARATOR
Intervention: Individual apartments
Number of subjects: 112
Study 1563193 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education and anticipatory guidance
Number of subjects: 7
Study 1563193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance concerning HIV
Number of subjects: 7
Study 3536770 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 212
Study 3536770 — intervention group
Group type: COMPARATOR
Intervention: Normal care facilities
Number of subjects: 212
Study 3536770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study 31147964 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI) system
Number of subjects: 40
Study 31147964 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical instrumentation
Number of subjects: 40
Study 30040763 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE) + Land-based exercises (LBE) (3/week + 2/week for 6 weeks)
Number of subjects: 60
Study 30040763 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercises (LBE) (5/week for 6 weeks)
Number of subjects: 60
Study 30040763 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE) + Land-based exercises (LBE)
Number of subjects: 60
Study 26799332 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=23)
Number of subjects: 40
Study 26799332 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+IPT (n=17)
Number of subjects: 40
Study 24867633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 111
Study 24867633 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 111
Study 24867633 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 111
Study 24867633 — intervention group
Group type: EXPERIMENTAL
Intervention: Any meniscal injury at baseline
Number of subjects: 111
Study 21863655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 51
Study 21863655 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 51
Study 21863655 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Healthy Subjects)
Number of subjects: 51
Study 16195983 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL)
Number of subjects: 15
Study 16195983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 12360154 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control with electrical cardioversion and antiarrhythmic drugs (amiodarone or other class III agents)
Number of subjects: 1450
Study 12360154 — intervention group
Group type: COMPARATOR
Intervention: Rate control with beta-blockers, digoxin, or pacemaker and AV nodal ablation
Number of subjects: 1450
Study 9549526 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with rhythmic auditory cues
Number of subjects: 30
Study 9549526 — intervention group
Group type: EXPERIMENTAL
Intervention: Training without rhythmic auditory cues
Number of subjects: 30
Study 9549526 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (baseline function)
Number of subjects: 30
Study 7975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine (ID-2)
Number of subjects: 225
Study 7975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hepatitis B vaccine (IM-10)
Number of subjects: 225
Study 7975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hepatitis B vaccine (IM-2)
Number of subjects: 225
Study 2658853 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional alarm using a wet sensor mat on the bed attached to an alarm bell out of reach of the child
Number of subjects: 56
Study 2658853 — intervention group
Group type: COMPARATOR
Intervention: Mini alarm system incorporating a tiny perineal wet sensor attached to a small alarm worn on the child's clothing
Number of subjects: 56
Study 805402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 276